Equillium reports lower-than-expected Q4 net loss

Equillium

25/03/2026 20:46

Overview

US biotechnology firm's fiscal Q4 net loss narrowed, beating analyst expectations

Outlook

Equillium plans to initiate Phase 1 EQ504 study in mid-2026, with data in late 2026

Company expects cash and equivalents, inclusive of the March 2026 financing, to fund operations into 2029

Result Drivers

R&D SPENDING DECLINE - Co said lower R&D expenses were primarily due to the wind down of clinical studies in 2025

Company press release: ID:nGNXpSrM4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
Beat
-$0.04
-$0.06 (4 Analysts)
Q4 Net Income
Beat
-$3.78 mln
-$5.06 mln (4 Analysts)
Q4 Operating Income
Beat
-$3.96 mln
-$4.73 mln (4 Analysts)
Q4 Operating Expenses
$3.96 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Equillium Inc is $4.50, about 130.8% above its March 24 closing price of $1.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)